Exploiting the PI3K/AKT pathway for cancer drug discovery.
Nat Rev Drug Discov
; 4(12): 988-1004, 2005 Dec.
Article
em En
| MEDLINE
| ID: mdl-16341064
ABSTRACT
Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy. Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway. This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Desenho de Fármacos
/
Transdução de Sinais
/
Fosfatidilinositol 3-Quinases
/
Proteínas Proto-Oncogênicas c-akt
/
Antineoplásicos
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2005
Tipo de documento:
Article